Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chiltern has acquired Theorem Clinical Research, strengthening its position as the largest mid-sized provider of comprehensive, yet flexible and responsive, clinical development services.
Subscribe to our email newsletter
Chiltern now comprises 3,700 people across 47 countries, expanding Chiltern’s footprint in Europe, North America and Asia-Pacific.
The acquisition enhances Chiltern’s oncology, biopharma and source offerings, broadens its therapeutic expertise and establishes new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.
Chiltern CEO Jim Esinhart said: "By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service.
"Clients can expect the same high level of service, now with expanded capabilities. Senior leadership will still be involved in running trials."
Chiltern chairman Nick Thornton said: "The acquisition of Theorem marks an important milestone for Chiltern.
"We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas. We are delighted to welcome the dynamic Theorem team to Chiltern and are pleased to announce that Dr. John Potthoff, Theorem’s president and CEO, has joined our board as a non-executive director."